IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
← catalyst calendarSponsored by Innate Pharma (industry) · IPH.PA — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
170actual
Sites
53
Countries
Austria, Belgium, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-05-22 | actual | When the study began enrolling |
| Primary completion | 2026-01-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-08 | actual | The whole study's end, after follow-up |
| First posted | 2019-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides/Sezary Syndrome
Intervention
- Biological: IPH4102 — also filed as lacutamab
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured From the first dose until study completion, an expected average of 2 years
Permalink · IPH.PA's whole pipeline · Catalyst calendar · Every registered study · What changed